On 8/16/24, Eagle Pharmaceuticals Inc (NASDAQ: EGRX) stock enjoyed a major increase of 13.8%, closing at $4.53. NORMAL trading volume accompanied the advance. The stock has risen 9.2% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, EGRX is expected to continue to be a modest Value Builder.
Eagle Pharmaceuticals has a current Value Trend Rating of B (Positive). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Eagle Pharmaceuticals has a very high Appreciation Score of 98 but a poor Power Rating of 25, with the Positive Value Trend Rating the result.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment